During CTA treatment, cancer patients frequently experience a significant reduction in red blood cells (anemia), leukocytes (leucopenia), neutrophils (neutropenia) and platelets (thrombocytopenia) typically treated with recombinant Erythropoietin (EPO), Granulocyte-Colony Stimulating Factor (G-CSF) and corticosteroids respectively. Here, CSF3 is linked to neutropenia.